Indications

• Chronic Lymphocytic Leukemia (CLL) (see Chronic Lymphocytic Leukemia, [[Chronic Lymphocytic Leukemia]])

---

Pharmacology

• Fully Human Monoclonal Antibody Against B-Cell Surface CD20 (see Anti-CD20 Therapy, [[Anti-CD20 Therapy]]): results in B-cell depletion

Metabolism

• xxxx

---

Administration

• xxxx

Dose Adjustment

• Hepatic:
• Renal:

---

Adverse Effects

Infectious Adverse Effects

Hepatitis B Reactivation (see Hepatitis B Virus, [[Hepatitis B Virus]])

• Epidemiology: reported with rituximab and ofatumumab
• Clinical
  • Acute Hepatitis (see Hepatitis, [[Hepatitis]])
  • Fulminant Hepatic Failure (FHF) (see Fulminant Hepatic Failure, [[Fulminant Hepatic Failure]])
• Prevention: recommended to screen patients for hepatitis B prior to anti-CD20 administration

Progressive Multifocal Encephalopathy (PML) (see Progressive Multifocal Leukoencephalopathy, [[Progressive Multifocal Leukoencephalopathy]])

• Epidemiology: reported with rituximab and ofatumumab
• Mechanism: anti-CD20 agents reactivate the latent JC polyoma virus, which has lytic effect on oligodenodrocytes in the brain

Other Adverse Effects

• xxx
• xxx
• xxx

---

References

• xxxx